The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors by Lochner, Martin & Thompson, Andrew James
Accepted Manuscript
The muscarinic antagonists scopolamine and atropine are competitive antagonists at
5-HT3 receptors
Martin Lochner, Andrew J. Thompson
PII: S0028-3908(16)30167-8
DOI: 10.1016/j.neuropharm.2016.04.027
Reference: NP 6279
To appear in: Neuropharmacology
Received Date: 6 November 2015
Revised Date: 9 March 2016
Accepted Date: 20 April 2016
Please cite this article as: Lochner, M., Thompson, A.J., The muscarinic antagonists scopolamine and
atropine are competitive antagonists at 5-HT3 receptors, Neuropharmacology (2016), doi: 10.1016/
j.neuropharm.2016.04.027.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
s
o
u
r
c
e
:
 
ht
tp
:/
/b
or
is
.u
ni
be
.c
h/
82
24
0/
 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The Muscarinic Antagonists Scopolamine and Atropine are 
Competitive Antagonists at 5-HT3 Receptors. 
 
Martin Lochner1 & Andrew J. Thompson2 
 
 
1
 Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012, 
Bern, Switzerland. Tel +41 31 631 4361. email: martin.lochner@dcb.unibe.ch 
 
 
2
 Dr Andrew J. Thompson, Department of Pharmacology, Tennis Court Road, Cambridge 
CB2 1PD, UK. Tel: +44 1223 334000. email: ajt44@cam.ac.uk 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
ABSTRACT  
Scopolamine is a high affinity muscarinic antagonist that is used for the prevention of 
post-operative nausea and vomiting. 5-HT3 receptor antagonists are used for the same 
purpose and are structurally related to scopolamine. To examine whether 5-HT3 receptors are 
affected by scopolamine we examined the effects of this drug on the electrophysiological and 
ligand binding properties of 5-HT3A receptors expressed in Xenopus oocytes and HEK293 
cells, respectively. 5-HT3 receptor-responses were reversibly inhibited by scopolamine with 
an IC50 of 2.09 µM. Competitive antagonism was shown by Schild plot (pA2 = 5.02) and by 
competition with the 5-HT3 receptor antagonists [3H]granisetron (Ki = 6.76 µM) and G-FL 
(Ki = 4.90 µM). The related molecule, atropine, similarly inhibited 5-HT evoked responses in 
oocytes with an IC50 of 1.74 µM, and competed with G-FL with a Ki of 7.94 µM. The reverse 
experiment revealed that granisetron also competitively bound to muscarinic receptors (Ki = 
6.5 µM). In behavioural studies scopolamine is used to block muscarinic receptors and induce 
a cognitive deficit, and centrally administered concentrations can exceed the IC50 values 
found here. It is therefore possible that 5-HT3 receptors are also inhibited. Studies that utilise 
higher concentrations of scopolamine should be mindful of these potential off-target effects. 
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 1 
INTRODUCTION 1 
Scopolamine is a high-affinity (nM) muscarinic antagonist that is used to treat 2 
post-operative nausea and vomiting, and motion sickness. As a research tool it is often 3 
administered to induce cognitive dysfunction. At higher doses it can also produce 4 
amnesia and compliance (Klinkenberg and Blokland, 2010). Atropine is a related 5 
muscarinic antagonist from the same biosynthetic pathway as scopolamine and is used 6 
as a cycloplegic and mydriatic in ophthalmology, and for the treatment of 7 
bradychardia. 8 
Scopolamine readily passes the blood brain barrier and it is believed that 9 
inhibition of muscarinic receptors in the central nervous system causes a cholinergic 10 
deficit that impairs memory (Klinkenberg and Blokland, 2010). As an age-related 11 
deterioration in cognitive function is thought to be predominantly related to a decline 12 
in cholinergic neurotransmission, scopolamine administration has often been used to 13 
model dementia (Bartus, 2000). Scopolamine has therefore been extensively used for 14 
preclinical and clinical testing of treatments for cognitive impairment (Bartolomeo et 15 
al., 2000; Blin et al., 2009; Liem-Moolenaar et al., 2011). 16 
In the clinic, 5-HT3 antagonists are mainly used for the treatment of nausea 17 
and vomiting following cancer therapy and general anaesthesia (Thompson 2013; 18 
Walstab et al., 2010). Experimentally, they can also be administered to reverse 19 
scopolamine-evoked learning and memory deficits (Barnes et al., 1990; Chugh et al., 20 
1991; Carli et al., 1997). In the brain 5-HT3 receptors are widely distributed in the 21 
amygdala and hippocampus, regions of critical importance in memory and spatial 22 
navigation, and involved in the control of emotional responses and their associated 23 
disorders such as anxiety and depression (Gulyas et al., 1999; Thompson and 24 
Lummis, 2007; Walstab et al., 2010). It is thought that the reversal of scopolamine-25 
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 2 
induced cognitive dysfunction by 5-HT3 receptor antagonists occurs by inhibiting pre-26 
synaptic 5-HT3 receptors that modulate the functions of other neurotransmitters such 27 
as acetylcholine, dopamine, γ-aminobutyric acid and glutamate in this region 28 
(Seyedabadi et al., 2014). A similar mechanism is thought to underlie the anti-29 
anxiolytic and anti-depressive actions of 5-HT3 antagonists. 30 
5-HT3 receptors are members of the Cys-loop family of ligand-gated ion 31 
channels (LGIC). These are responsible for fast excitatory and inhibitory 32 
neurotransmission in the central and peripheral nervous systems. The family includes 33 
nicotininc acetylcholine (nACh), γ-aminobutyric acid (GABAA) and glycine 34 
receptors, which are all cell-surface, transmembrane ion channels. They consist of 35 
five subunits that surround a central ion-conducting pore, and each subunit contains 36 
three distinct functional regions that are referred to as the extracellular, 37 
transmembrane and intracellular domains. The orthosteric binding site (that occupied 38 
by the endogenous agonist) is located between the extracellular domains of adjacent 39 
subunits, and is formed by the convergence of three amino acid loops from the 40 
principal subunit (loops A - C) and three β-sheets (loops D - F) from the 41 
complementary subunit (Thompson et al., 2008). Agonist binding results in the 42 
opening of a central ion-conducting pore that is located within the transmembrane 43 
domain (Peters et al., 2010; Hassaine et al., 2014). Ligands bind to both domains, but 44 
the orthosteric binding site is the main drug target. These 5-HT3 receptor competitive 45 
antagonists have high affinities (nM) and conform to a pharmacophore that consists of 46 
an aromatic group coupled to an azabicyclic ring via a carbonyl linker (fig 1). Both 47 
atropine and scopolamine also have these structural features, suggesting that these 48 
muscarinic antagonists could also bind at 5-HT3 receptors (Thompson, 2013). 49 
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 3 
Here we use a combination of electrophysiology, radioligand binding, flow 50 
cytometry and in silico ligand docking to provide evidence that, in addition to its 51 
block of muscarinic receptors, scopolamine is also a competitive antagonist of 5-HT3 52 
receptors. 53 
 54 
Granisetron
N
H
HO
NH2
5-HT
HO
O
O
N
O
Scopolamine
HO
O
O
N
Atropine
*
N
N
O
H
N
N
HO
O
O
N
O
[3H]N-Methylscopolamine
# = [3H]
#
OO
NH
N
O
SDZ-ICT 322
O
N
O
NH
Tropisetron
 55 
 56 
Figure 1 57 
Chemical structures of endogenous agonist 5-HT, 5-HT3 receptor antagonists 58 
granisetron, tropisetron and SDZ-ICT 322, scopolamine, atropine and the radioligand 59 
[3H]N-methylscopolamine. Note that scopolamine is a single enantiomer whereas 60 
atropine is a mixture of epimers at the indicated (asterisk) carbon atom. 61 
 62 
MATERIALS AND METHODS 63 
Materials: Atropine and scopolamine were from Sigma-Aldrich (St. Louis, 64 
MO, USA). [3H]N-methylscopolamine (84 Ci/mmol) was from Perkin Elmer (Boston, 65 
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MA, USA). Human 5-HT3A (Accession: 46098) subunit cDNA was kindly provided 66 
by J. Peters (Dundee University, UK). 67 
Oocyte Maintenance: Xenopus laevis oocytes were purchased from EcoCyte 68 
Bioscience (Castrop-Rauxel, Germany) and maintained according to standard 69 
methods (Goldin, 1992) in ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM 70 
HEPES, pH 7.4). 71 
 Cell culture: Human embryonic kidney (HEK) 293 cells were grown on 90 72 
mm round tissue culture plates as monolayers in DMEM / F12 (Gibco, Life 73 
Technologies, CA, USA) supplemented with 10% fetal bovine serum (FBS; Sigma 74 
Aldrich) at 37°C in a moist atmosphere containing 5% CO2.  75 
5-HT3 Receptor Expression: 5-HT3A subunit cDNA was cloned into 76 
pGEMHE for oocyte expression. cRNA was in vitro transcribed from linearised 77 
plasmid cDNA template using the mMessage mMachine Ultra T7 Transcription kit 78 
(Ambion, Austin, Texas, USA). Stage V and VI oocytes were injected with 50 nl of 79 
100-600 ng / µl cRNA (5 - 25 ng injected), and currents were recorded 1 - 3 days 80 
post-injection.  81 
5-HT3A subunit cDNA was cloned into pcDNA3.1 for expression in HEK 293 82 
cells. Cells were transiently transfected with this cDNA using polyethyleneimine 83 
(PEI: 25 kDa, linear, powder, Polysciences Inc., Eppelheim, Germany). 30 µl of PEI 84 
(1 mg ml−1), 5 µl cDNA and 1 ml DMEM were incubated for 10 min at room 85 
temperature, added drop wise to a 90mm plate, at 80 - 90% confluency, and incubated 86 
for 2–3 days before harvesting.  87 
Muscarinic Receptor Preparation:  Muscarinic receptors were isolated from 88 
the cerebral cortices of adult male Guinea pigs (200-300 g). Brains were dissected 89 
into 10 mM Tris-HCl + 1 mM EDTA (pH 7.6) on ice and homogenised using a 90 
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 5 
Teflon-glass homogeniser with a motor-driven pestle (30 s, 300 rpm). The tissue was 91 
pelleted 17,000 g for 30 min and the membranes resuspended, and then centrifuged 92 
again using the same procedure. The final pellet was homogenised in 10 mM HEPES 93 
buffer (pH 7.4) and used directly for radioligand binding. Experiments involving 94 
animals were approved by the University of Cambridge Animal Welfare and Ethical 95 
Review Body (PHARM 004/15).  96 
Radioligand Binding:  Saturation binding (8 point) curves were measured by 97 
incubating either crude extracts of HEK 293 cells stably expressing 5-HT3 receptors, 98 
or Guinea pig membrane preparations, in 0.5 ml incubations containing 10 mM 99 
HEPES buffer (pH 7.4) and 0.1 – 1 nM [3H]granisetron or 1 – 10 nM [3H]N-100 
methylscopolamine. Competition binding (10 point) was determined by incubating the 101 
same receptors preparations in 0.5 ml HEPES buffer containing either 0.6 nM 102 
[3H]granisetron or 0.6 nM [3H]N-methylscopolamine, and differing concentrations of 103 
competing ligands. Non-specific binding was determined with 1 mM quipazine or 10 104 
µM scopolamine respectively. Incubations were terminated by filtration onto 105 
Whatman GF / B filters (Sigma Aldrich) wetted with HEPES buffer + 0.3 % 106 
polyethyleneimine, followed by two rapid washes with ice-cold HEPES buffer. 107 
Protein concentration was calculated using a Lowry protein assay with bovine serum 108 
albumin standards (Lowry et al., 1951). Radioactivity was measured using a Tri-Carb 109 
2100TR (Perkin Elmer, Waltham, MA, USA) scintillation counter. 110 
Flow Cytometry:  HEK 293 cells expressing the 5-HT3 receptor were grown in 111 
monolayers and harvested from 90 mm culture dishes using 10 ml Trypsin-EDTA 112 
(Sigma Aldrich) for 10 min at 37oC. Digestion was terminated by the addition of 25 113 
ml DMEM + 10% FBS and cells pelleted at low speed for 2 min. The pellet was 114 
resuspended in 3 ml phosphate buffered saline (PBS: 137 mM NaCl, 8.0 mM 115 
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Na2HPO4, 2.7 mM KCl, 1.47 mM KH2PO4, pH 7.4) and cells filtered through a cell 116 
strainer (BD Falcon, Franklin Lakes, NJ, USA). Competition binding was measured 117 
by incubating HEK 293 cells with different concentrations of non-labeled ligands and 118 
10 nM G-FL (Jack et al., 2015; Lochner and Thompson, 2015). After 10 min 119 
incubation, cells were pelleted and rapidly washed in PBS before being resuspended 120 
in the same buffer and analysed on a BD Accuri C6 flow cytometer (Becton, 121 
Dickinson and Company, NJ, USA) at 488 nm excitation / 530 nm emission. 122 
Electrophysiology: Using two electrode voltage clamp, Xenopus oocytes were 123 
routinely clamped at -60 mV using an OC-725 amplifier (Warner Instruments, 124 
Connecticut, USA), NI USB-6341 X Series DAQ Device (National Instruments, 125 
Berkshire, UK) and the Strathclyde Electrophysiology Software Package (University 126 
of Strathclyde, UK). Micro-electrodes were fabricated from borosilicate glass 127 
(GC120TF-10, Harvard Apparatus, Edenbridge, Kent, UK) using a two stage 128 
horizontal pull (P-1000, Sutter Instrument Company, California, USA) and filled with 129 
3 M KCl. Pipette resistances ranged from 0.7 - 1.5 MΩ. Oocytes were routinely 130 
perfused with ND96 at a rate of 15 ml min-1. Drug application was via a simple 131 
gravity fed system calibrated to run at the same rate. Antagonists were routinely co-132 
applied in the presence of 2 µM 5-HT or continuously applied for 1 min before the co-133 
application of 2 µM 5-HT. A 2 min wash was used between applications. 134 
Data Analysis: All data analysis was performed with GraphPad Prism v5.00 135 
(GraphPad Software, San Diego, CA, USA). For concentration-response curves, peak 136 
currents were measured for each concentration of agonist and normalised to the peak 137 
current in the same oocyte. For inhibition curves, the peak current response to 2 µM 138 
5-HT was measured at in the absence or presence of antagonist and normalised to the 139 
response to 2 µM 5-HT alone. The mean and S.E.M. for a series of oocytes was 140 
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 7 
plotted against agonist or antagonist concentration and iteratively fitted to the 141 
following equation: 142 
 143 
         (Equ. 1) 144 
where Imin is the baseline current, Imax is the peak current evoked by agonist, EC50 is 145 
the concentration of agonist needed to evoke a half-maximal response, x is the ligand 146 
concentration and nH is the Hill slope. Kb was estimated from IC50 values using the 147 
Cheng-Prusoff equation with the modification by Leff and Dougall (1993):((Leff and 148 
Dougall, 1993) 149 
(Equ. 2) 150 
where Kb is the dissociation constant of the competing drug, IC50 is the concentration 151 
of antagonist required to half the maximal response, [A] is the agonist concentration, 152 
[A50] is the agonist EC50, and nH is the Hill slope of the agonist. 153 
Analysis of competitive inhibition was performed by Schild Plot according to 154 
the following equation: 155 
    log[(EC50’/EC50) -1] = log[L] – logKb  156 
         (Equ. 3) 157 
where EC50’ and EC50 are values in the presence and absence of antagonist (Dose 158 
Ratio), [L] is the concentration of antagonist, and Kb is the equilibrium dissociation 159 
constant for the antagonist receptor interaction. Further analysis was performed using 160 
the Gaddum-Schild equation (slope = 1) as recommended by Neubig et al 161 
(2003):(Neubig et al., 2003) 162 
 163 
         (Equ. 4) 164 
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L + R                 LR 
where pEC50 is the negative logarithm of the agonist EC50, [L] is the antagonist 165 
concentration, logC is a constant and pA2 is the negative logarithm of the antagonist 166 
concentration needed to double the concentration of agonist required in order to elicit 167 
a response that is comparable to the original response in the absence of antagonist. 168 
pA2 is equal to the negative logarithm of Kb when the slope of the Schild plot is 169 
exactly 1. 170 
Kinetic parameters were determined according to the following model of a 171 
simple bimolecular binding scheme: 172 
  173 
         (Equ. 5) 174 
where L is the free ligand concentration, R is receptor concentration, LR is the ligand-175 
receptor complex and kon and koff are the microscopic association and dissociation rate 176 
constants. In a simple scheme such as this, the equilibrium dissociation constant (Kd) 177 
is equal to the ratio of dissociation to association rate constants, such that:  178 
 179 
         (Equ. 6) 180 
According to a one site binding model of the type shown, the time constants for the 181 
onset and recovery of an antagonist response can be used to estimate k+1 and k-1: 182 
 183 
      1/τoff = k-1  (Equ. 7) 184 
and 185 
     1/τon = k+1[L] + k-1  (Equ. 8)  186 
where τon refers to the time constant for the onset of inhibition, τoff refers to recovery 187 
from inhibition and [L] is antagonist concentration.  188 
Competition binding data were analysed by iterative curve fitting according to: 189 
on
off
k
k
K =d
koff 
kon 
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         (Equ 9) 190 
Ki values were determined from the IC50 values using the Cheng-Prusoff 191 
equation: 192 
(Equ. 10)  193 
where Ki is the equilibrium dissociation constant for binding of the unlabeled ligand, 194 
[L] is the concentration of labeled ligand and Kd is the equilibrium dissociation 195 
constant of the labeled ligand. 196 
Docking: We used a template of granisetron bound to 5HTBP (PDB ID 197 
2YME); an AChBP chimaera with substitutions in the binding site that mimic the 5-198 
HT3 receptor (Kesters et al., 2013). The three-dimensional structure of the 199 
hydrochloride salt of scopolamine was extracted from the Cambridge Structural 200 
Database (CSD, access code KEYSOW) and Chem3D Pro v14.0 (CambridgeSoft, 201 
Cambridge, UK) was used to construct scopolamine based on the crystal structure. 202 
The generated ligand was subsequently energy-minimised using the implemented 203 
MM2 force field. Similarly, construction of the three-dimensional structure of the 204 
protonated form of tropisetron was based on the crystal structure of N-methyl 205 
tropisetron (CSD access code BEGLEG), and the three-dimensional structure of SDZ-206 
ICT 322 was based on the crystal structures of N-methyl tropisetron (for the indole 207 
carboxylic moiety; CSD access code BEGLEG) and scopolamine (for the tricyclic 208 
scopine moiety; CSD access code KEYSOW), followed by energy-minimisation. The 209 
binding site was defined as being within 10 Å of the centroid of the aromatic side-210 
chain of W183, a residue that is centrally located in the binding site and is important 211 
for the binding of other 5-HT3 competitive ligands. The ligands were docked into this 212 
site using GOLD Suite v5.3 (The Cambridge Crystallographic Data Centre, 213 
Cambridge, UK) with the GoldScore function and default settings. For docking, 214 
dKL
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K
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scopolamine was defined as flexible, while the C-C bond between the ester group and 215 
the aromatic indole ring of SDZ-ICT322 and tropisetron was defined as rigid due to 216 
conjugation. Ten docked poses were generated for each ligand and the poses 217 
visualized with PyMol v1.7.5.0. 218 
 219 
RESULTS 220 
Effects of scopolamine on 5-HT3 receptor currents: Application of 5-HT to 221 
Xenopus oocytes expressing the 5-HT3 receptor produced concentration-dependent, 222 
rapidly activating, inward currents that slowly desensitised (τ = 42 ± 5 seconds; n = 8) 223 
over the time-course of the applications. Plotting current amplitude against a series of 224 
5-HT concentrations allowed the data to be fitted with Equ 1 to give a pEC50 of 5.65 ± 225 
0.02 (EC50 = 2.24 µM, n = 6) and Hill slope of 2.06 ± 0.14 (fig 2A). Agonist responses 226 
were completely inhibited by the established 5-HT3 receptor-specific antagonist 227 
granisetron (100 nM, data not shown). Uninjected oocytes did not respond to 5-HT. 228 
Application of scopolamine to oocytes expressing 5-HT3 receptors did not 229 
elicit a response when applied alone, but caused a concentration-dependent inhibition 230 
of the response during a co-application of 2 µM 5-HT (fig 2). The pIC50 value for 231 
scopolamine was 5.68 ± 0.05 (IC50 = 2.09 µM, n = 6) with a Hill Slope of 1.06 ± 0.05. 232 
This gave a Kb of 3.23 µM (Equ 2). The same concentration-dependent effect was also 233 
seen when scopolamine was applied during the 5-HT application (fig 2C). Using this 234 
protocol the onset of inhibition could be fitted with a mono-exponential function and 235 
the reciprocal plotted against antagonist concentration to yield association (slope; kon 236 
= 2.6 x 104 M-1 s-1) and dissociation (y-axis intercept; 0.32 s-1) rates that gave a Kd of 237 
12.3 µM (fig 2D, Equ .6). Inhibition was fully reversible after 1 minute of washing 238 
and was unaltered by a 1 min scopolamine pre-application (data not shown). 239 
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 240 
 241 
A      B 242 
 243 
 244 
 245 
 246 
 247 
 248 
 C      D  249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
Figure 2 259 
The effect of scopolamine on 5-HT3 receptor currents. (A) Concentration-response 260 
curve for 5-HT. (B) Concentration-inhibition of the 2 µM 5-HT response by co-261 
applied scopolamine. The data in 2A are normalised to the peak current response for 262 
each oocyte and represented as the mean ± S.E.M. for a series of oocytes. In fig 2B, 263 
inhibition by scopolamine is shown relative to the peak current response to 2 µM 5-264 
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HT alone. For 5-HT curve fitting yielded a pEC50 of 5.65 ± 0.02 (EC50 = 2.24 µM, n = 265 
6) and Hill slope of 2.06 ± 0.14. The pIC50 value for scopolamine was 5.68 ± 0.05 266 
(IC50 = 2.09 µM, n = 6) with a Hill Slope of 1.06 ± 0.05. (C) Sample traces showing 267 
the onset (τon) and recovery (τoff) of scopolamine inhibition (grey bar) during a 2 µM 268 
5-HT application (filled bar). (D) Onset of inhibition was well fitted by mono-269 
exponential functions to give kobs (n = 17). A plot of the reciprocal of these time 270 
constants versus the scopolamine concentration showed a linear relationship where 271 
the slope = kon (1.61 x 104 M-1 s-1) and the y-axis intercept = koff (0.37 s-1). 272 
 273 
Mechanism of scopolamine block: Increasing concentrations of scopolamine 274 
(10 µM, 30 µM, 60 µM, 100 µM, 300 µM) caused a parallel rightward shift in the 5-275 
HT concentration-response curve, with no change in the maximal response (fig 3A, 276 
table 1). A Schild plot of these results (fig 3B), yielded a gradient close to 1 (1.06 ±
 
277 
0.10, R2 = 0.97) and a pA2 value of 5.03 ± 0.43 (Kb = 9.33 µM). The Kb estimate was 278 
similar (2.88 µM) if the data were fitted using a nonlinear regression method (Equ. 4) 279 
as recommended by Neubig et al (2003) and Lew and Angus (1995). These data 280 
support a competitive mechanism of action, indicating that scopolamine binds to the 281 
orthosteric binding site. (Lew and Angus, 1995) 282 
 283 
Table 1 284 
Parameters derived from concentration-response curves in the presence of increasing 285 
concentrations of scopolamine. 286 
[Scopolamine] 
(µM) 
pEC50 EC50 (µM) nH n 
Control 5.65 ± 0.02 2.24 2.1 6 
10 5.49 ± 0.04 3.23 2.2 4 
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30 5.15 ± 0.01 7.08 3.3 4 
60 4.87 ± 0.03 13.5 3.4 4 
100 4.84 ± 0.04 14.4 3.9 3 
300 4.36 ± 0.03 43.6 2.5 5 
 287 
Binding at 5-HT3 and muscarinic receptors: To further test for a 288 
competitive binding at the 5-HT3 receptor, we measured competition of unlabelled 289 
scopolamine with [3H]granisetron, an established high-affinity competitive antagonist 290 
at these receptors. Scopolamine displayed concentration-dependent competition with 291 
0.6 nM [3H]granisetron (~ Kd, fig. 4), yielding an average pKi (Equ. 10) of 5.17 ± 0.24 292 
(fig 4; Ki = 6.76 µM, n = 3). 293 
 294 
A      B 295 
 296 
 297 
 298 
 299 
 300 
Figure 3 301 
The mechanism of 5-HT3 receptor inhibition by scopolamine. (A) Concentration-302 
response curves were performed in the absence or presence of the indicated 303 
concentrations of scopolamine. The curves showed parallel dextral shifts with 304 
maximal currents restored by increasing concentrations of 5-HT. Parameters derived 305 
from these curves can be seen in table 1. (B) A Schild plot was created from the dose 306 
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ratios of the curves shown in 3A and fitted with Equ. 3. to yield a slope of 1.06 ±
 
0.10 307 
(R2 = 0.97) and a pA2 of  5.03 ± 0.43 (Kb, 2.88 µM). 308 
 309 
 310 
Saturation binding using radiolabelled scopolamine was also undertaken at 5-311 
HT3 receptors. Although the Ki of scopolamine was too low to accurately measure 312 
binding, the compound [3H]N-methylscopolamine that we used contains a permanent 313 
quaternary amine that increases its affinity at nicotinic receptors (fig. 1, Schmeller et 314 
al., 1995). However, at concentrations of up to 10 nM, no saturable binding was 315 
observed for this radioligand at 5-HT3 receptors. 316 
Competition of scopolamine was also measured at 5-HT3 receptor by flow 317 
cytometry with a fluorescently labelled form of granisetron (G-FL, (Jack et al., 318 
2015)). Concentration-dependent competition of G-FL with scopolamine gave an 319 
average pKi (Equ. 11) of 5.31 ± 0.09 (fig 4; Ki = 4.90 µM, n = 8). This is similar to the 320 
affinities measured using electrophysiology and radioligand binding and provides 321 
further support for a competitive mode of action.  322 
In the reverse experiment, competition binding of granisetron with [3H]N-323 
methylscopolamine was examined at muscarinic receptors. The IC50 for granisetron at 324 
muscarinic receptors was 14.1 ± 3.1 µM (n = 7), yielding a Ki of 6.5 µM (Equ. 10). 325 
Properties of atropine: Atropine is a structurally related muscarinic 326 
antagonist (fig. 1). To test its pharmacological properties we performed measurements 327 
using electrophysiology and flow cytometry. In oocytes expressing 5-HT3 receptors, 328 
atropine did not elicit a response when applied alone, but it caused concentration-329 
dependent inhibition of the 2 µM 5-HT-evoked response with a pIC50 of 5.76 ± 0.14 330 
(IC50 = 1.74 µM, n = 5) and Hill Slope of 1.06 ± 0.05 (fig 5A). This yielded a Kb of 331 
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1.89 µM (Equ 2). Inhibition was fully reversible after 1 minute of washing and was 332 
unaltered by pre-application (data not shown).  333 
Competition of G-FL and atropine was also shown by flow cytometry (fig 334 
5B). Concentration-dependent measurements were fitted to give a pKi (Equ 10) of 335 
5.10 ± 0.16 (Ki = 7.94 µM, n = 5). 336 
 337 
A      B 338 
 339 
 340 
 341 
 342 
 343 
 344 
Figure 4 345 
Competition of scopolamine with an established 5-HT3 receptor antagonist. (A) 346 
Radioligand binding curves for the competition of 0.6 nM [3H]granisetron and 347 
varying concentrations of scopolamine at crude membrane extracts of 5-HT3 receptors 348 
from stably expressing HEK 293 cells. Data was normalised to [3H]granisetron 349 
binding in the absence of antagonist and fitted with Equ. 10. The curve is 350 
representative of 3 similar experiments, which gave an average pKi of 5.17 ± 0.24 (Ki 351 
= 6.76 µM, n = 3). (B) Flow cytometry, showing the competition of 10 nM G-FL (a 352 
fluorescent derivative of granisetron; Jack et al., 2015) and varying concentrations of 353 
scopolamine at 5-HT3 receptors expressed on the surface of live HEK 293 cells. The 354 
average pKi of these experiments was similar to values from radioligand competition 355 
(5.31 ± 0.09, Ki = 4.90 µM, n = 8). 356 
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 357 
 358 
A       B 359 
 360 
 361 
 362 
 363 
 364 
Figure 5 365 
Effects of atropine on the electrophysiological responses to 5-HT and binding of G-366 
FL. (A) Concentration-inhibition of the 2 µM 5-HT response by co-applied atropine. 367 
For each oocyte the responses in the presence of antagonist are normalised to the peak 368 
current response to 5-HT alone and data represented as the mean ± S.E.M. for a series 369 
of oocytes. Curve fitting yielded a pIC50 of 5.76 ± 0.14 (IC50 = 1.74 µM, n = 5) and 370 
Hill Slope of 1.06 ± 0.05. (B) Flow cytometry, showing the competition of 10 nM G-371 
FL (a fluorescent derivative of granisetron; Jack et al., 2015) and varying 372 
concentrations of atropine at 5-HT3 receptors expressed on the surface of live HEK 373 
293 cells. The affinity (pKi = 5.10 ± 0.16, Ki = 7.94 µM, n = 5) of atropine calculated 374 
from these experiments was similar to that measured using electrophysiology. 375 
 376 
Docking studies: Based upon the evidence that scopolamine binds at the 377 
orthosteric binding site we used a bio-informatics approach to probe possible ligand 378 
orientations and try to understand why the affinity of scopolamine was lower than 379 
other established 5-HT3 receptor antagonists. To this end we chose a crystal structure 380 
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of a 5-HT3 receptor-AChBP chimera (termed 5HTBP) complexed with granisetron 381 
(PDB ID: 2YME) as a binding site model (fig 6A, Kesters et al., 2013). For the 382 
purpose of validation we first removed granisetron from the template and re-docked 383 
both this ligand and the closely related 5-HT3 receptor antagonist, tropisetron, into the 384 
binding site template. The proposed ligand orientations of these two antagonists were 385 
almost identical to the binding pose from the crystal structure 2YME. This is 386 
illustrated in fig. 6B where tropisetron is shown with its bicyclic moiety located 387 
between the aromatic side chains of W90, W183 and Y234 and the flat indole ring is 388 
sandwiched between loop C and R92 from loop D.  389 
Following from our docking with established 5-HT3 antagonists, we 390 
performed docking with scopolamine. This yielded a docked pose cluster (fig. 6C) 391 
that placed the scopine head of scopolamine at the same location as the azabicyclic 392 
rings of granisetron and tropisetron, but owing to the flexibility of scopolamine and 393 
the steric restraints imposed by the tight binding cavity, the hydroxyl of the carbonyl 394 
linker was extended into a pocket at the rear of the binding site, displacing the 395 
aromatic ring by ~ 3 Å towards the principal binding interface (fig 6D). 396 
SDZ-ICT 322 (fig. 1), is a competitive, highly potent 5-HT3 receptor 397 
antagonist that contains key structural elements of both scopolamine and high affinity 398 
5-HT3 receptor antagonists such as granisetron and tropisetron (Blum et al., 1992); it 399 
has the same tricyclic scopine moiety as scopolamine, which is rigidly linked to the 400 
flat heteroaromatic group (indole) found in granisetron and tropisetron. Docking of 401 
SDZ-ICT 322 into the 5-HT3 receptor binding site predicted an orientation similar to 402 
granisetron and tropisetron, with its aromatic indole group close to the side chain of 403 
R92 from loop D and the scopine tricycle pointing towards the β-sheets of the 404 
principal face, surrounded by the aromatic rings of W90, W183 and Y234 (fig. 6E).  405 
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Figure 6 431 
epresentative examples of 5-HT3 receptor antagonists (ball-and-stick representation) 432 
docked into a 5-HT3 receptor orthosteric binding site model (PDB ID: 2YME; a co-433 
crystal of granisetron bound to a mutant AChBP that contains residues from the 5-HT3 434 
receptor binding site (termed 5HTBP; Kesters et al., 2013) and important binding site 435 
residues (stick representation). Principle face (left-hand side, light grey), 436 
complementary face (right-hand side, dark grey).  (A) 2YME from the side (y-axis) 437 
showing the location of granisetron (green) in the orthosteric binding site at the 438 
interface of two adjacent subunits. (B) Proposed binding pose for tropisetron (blue) 439 
overlaying granisetron (green) from the co-crystal structure 2YME. (C) The proposed 440 
binding pose for scopolamine (orange) showing its orientation in the 5-HT3 binding 441 
site. (D) A surface representation of 5HTBP bound with granisetron and an overlay of 442 
docked scopolamine showing the hydroxyl of the carbonyl linker that, owing to steric 443 
constraints, is located within a cavity at the rear of the binding site. It can be seen that 444 
while the scopine head of scopolamine (orange) is at the same location as the 445 
azabicyclic rings of granisetron (green), the steric bulk, flexibility and presence of a 446 
hydroxyl in the linker region results in the aromatic ring being orientated away from 447 
loops D and F. (D) In contrast, the proposed binding pose for SDZ-ICT 322 (yellow) 448 
is more similar to that of granisetron. For chemical structures of the described ligands 449 
see fig. 1. 450 
 451 
DISCUSSON 452 
This study describes the effects of scopolamine and atropine on human 5-HT3 453 
receptors. Both compounds were antagonists with µM potencies. For scopolamine, 454 
binding at the orthosteric site was demonstrated by Schild analysis and competition 455 
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with the 5-HT3 receptor antagonists [3H]granisetron and G-FL. In silico docking 456 
predicted that molecular features of the carbonyl linker of scopolamine may alter its 457 
orientation within the binding site and could account for the lower potency when 458 
compared to established 5-HT3 receptor antagonists. Evidence for this is discussed in 459 
more detail below. 460 
The observation that scopolamine competitively inhibits 5-HT3 receptor 461 
responses was anticipated as it has structural similarities with other 5-HT3 receptor 462 
antagonists (fig 1) and ligand promiscuity at 5-HT3 receptors has been reported 463 
elsewhere. For example, epibatidine and tropisetron are high affinity agonists of α7 464 
nACh and high affinity antagonists of 5-HT3 receptors. Similarly, 5-HT3 receptors 465 
also have lower affinity competitive interactions with dopamine, acetylcholine, 466 
nicotine, d-tubocurarine, chloroquine, varenecline and strychnine, as well as allosteric 467 
modulators such as anaesthetics, alcohols, steroids and terpenoids and the non-468 
competitive antagonists picrotoxin, ginkgolides and mefloquine (Thompson and 469 
Lummis, 2008; Thompson and Lummis, 2013; Thompson et al., 2014). It is perhaps 470 
more surprising that the affinities of scopolamine and atropine were not higher given 471 
their structural similarities to 5-HT3 receptor antagonists that bind with nM affinities. 472 
However, the lower affinities are likely to result from both scopolamine and atropine 473 
having an aromatic ring that is not directly attached to the ester moiety that forms the 474 
link with the bicyclic amine, a bond that is common to all 5-HT3 receptor antagonists 475 
(Thompson, 2013). The direct conjugation of the carbonyl (ester or amide) group with 476 
the aromatic ring provides 5-HT3 receptor antagonists with planarity and rigidity that 477 
is crucial for potent inhibition and high-affinity binding (Hibert, 1994). Instead, 478 
scopolamine and atropine have linkers that contain a tetrahedral carbon that carries a 479 
polar hydroxymethyl substituent (fig 1). The importance of this region is highlighted 480 
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by SDZ-ICT 322, a ligand that is also a high affinity 5-HT3 receptor antagonist (pA2 = 481 
10.6 in isolated rabbit vagus nerve, pKd = 9.2 in N1E cells) but has the same scopine 482 
tricyclic moiety as scopolamine directly linked to the aromatic indole ring (Blum et 483 
al., 1992). This hypothesis is further supported by the low affinity of atropine which 484 
contains the same tetrahedral carbon, while the close analogue tropane benzoate, with 485 
a carbonyl linker, has high affinity at 5-HT3 receptors (63 nM; Fozard 1989). We also 486 
found that the potent 5-HT3 receptor antagonist, granisetron, binds with a micromolar 487 
affinity at muscarinic receptors, suggesting that while general conformations of these 488 
ligands enable them to share common binding sites at both receptors, the linkers are 489 
likely to confer the key structural elements that drive receptor selectivity. 490 
To find further evidence for the importance of this linker region, we performed 491 
docking into a homologue of the 5-HT3 receptor that has been co-crystallised with the 492 
antagonist granisetron in its binding site (Kesters et al., 2013). The predicted binding 493 
pose for the high affinity antagonist SDZ-ICT 322 was similar to the orientations of 494 
granisetron and tropisetron ligands in 5HTBP and AChBP co-crystal structures (fig 495 
6E), which was anticipated given the similarity in their structures (fig. 1) and affinities 496 
(Hibbs et al., 2009; Kesters et al., 2013). However, in scopolamine the tri-substituted 497 
tetrahedral carbon between the scopine tricyclic moiety and the aromatic phenyl ring 498 
leads to a kink in the molecular structure, unlike the high-affinity 5-HT3 receptor 499 
which are planar. In scopolamine this linker also contains a hydroxyl group. The 500 
docking results lead us to speculate that the substituted tetrahedral carbon in 501 
scopolamine creates increased bulk and ligand flexibility, while the polar hydroxyl 502 
group is sterically restricted and occupies a cavity in the rear of the binding site. If 503 
these predictions are correct, the differences in the linker region orientate scopolamine 504 
away from residues in binding loops D and F (fig 6D), and the ligand no longer 505 
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engages with residues that are essential for high affinity binding (Thompson et al., 506 
2005; Thompson et al., 2006). 507 
Scopolamine is generally regarded as a non-selective muscarinic receptor 508 
antagonist with an affinity ≤ 1 nM. At higher concentrations it also blocks nicotinic 509 
acetylcholine receptors (IC50 = 928 µM) and increases the expression of α7 nACh 510 
receptors (Schmeller et al., 1995; Falsafi et al., 2012). When using scopolamine for 511 
the prevention of motion sickness in humans, blood concentrations following 512 
transdermal and combined oral administration have been reported to peak at ~0.37 ng 513 
ml-1 within an hour (Nachum et al., 2001). Elsewhere, higher plasma concentrations 514 
of 2.9 ng ml-1 are reported following intravenous administration (0.4 mg) to healthy 515 
volunteers (Putcha et al., 1989). Both of these values are significantly lower than the 516 
concentrations that affect 5-HT3 receptors and it is unlikely that these receptors would 517 
be inhibited. However, when scopolamine is used to induce cognitive dysfunction in 518 
rodents, intraperitoneal or sub-cutaneous injections of up to 2 mg kg-1 are used 519 
(Klinkenberg and Blokland, 2010). As a weight per volume this is the equivalent of 520 
~1 µM which is close to the IC50 at 5-HT3 receptors. For centrally administered 521 
scopolamine the focal concentrations at the site of administration can be as high as 522 
140 µg µl-1 (460 µM), a concentration that is far in excess of its IC50 at 5-HT3 523 
receptors and would cause complete inhibition (Klinkenberg and Blokland, 2010). 524 
The amygdala and hippocampus are of critical importance in implicit and 525 
explicit memory, and this function is mediated via actions of both cholinergic and 526 
serotonergic pathways. As scopolamine blocks muscarinic receptors with high affinity 527 
it is used to induce cognitive dysfunction, but it is also known that 5-HT3 receptor 528 
antagonists alleviate these symptoms. Long-term potentiation (LTP, the neural 529 
mechanism through which memory is formed) in the amygdala and hippocampus is 530 
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inhibited by 5-HT3 receptor agonists and promoted by antagonists (Staubli and Xu, 531 
1995). These effects are probably mediated via actions on the GABA-ergic synaptic 532 
activity of interneurons, but may also result from activities at 5-HT3 receptors that are 533 
present outside of the hippocampus and would also be blocked by systemically 534 
administered 5-HT3 antagonists. If sufficiently high concentrations of scopolamine 535 
were centrally administered we might expect a similar block of 5-HT3 receptors which 536 
could complicate the interpretation of its physiological effects. Pre-administering 5-537 
HT3 antagonists to alleviate cognitive dysfunction might further complicate these 538 
studies as their higher affinities and slower elimination from the body would prevent 539 
scopolamine binding at 5-HT3 receptors (Putcha et al., 1989). As mood disorders such 540 
as anxiety and depression are also mediated by both cholinergic and serotonergic 541 
pathways, the interpretation of scopolamine effects on these might be similarly 542 
affected (Bétry et al., 2011). 543 
In summary, we provide the first reported evidence that the drug scopolamine 544 
inhibits the function of homomeric 5-HT3 receptors via a competitive mode of action, 545 
and suggest that the bond that links the kinked and more flexible structure of 546 
scopolamine is responsible for the lower affinity when compared with other typically 547 
flat and rigid 5-HT3 receptor antagonists. Because the concentration of centrally 548 
administered scopolamine can exceed the concentration that inhibits 5-HT3 receptors, 549 
it is likely that these receptors would be inhibited under this experimental paradigm, 550 
and could influence LTP. Given this finding we believe that the potential effects at 5-551 
HT3 receptors should be considered before centrally administering high 552 
concentrations of this compound. 553 
 554 
 555 
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• Muscarinic ligands scopolamine and atropine also have micromolar affinity at 5-HT3 
receptors. 
• The 5-HT3 receptor ligand granisetron also has micromolar affinity at muscarinic receptors 
• Scopolamine has a tetrahedral carbon linker that is responsible for its lower affinity at 5-HT3 
receptors. 
• Scopolamine is used as a preclinical model for inducing cognitive dysfunction. 
• Use of high concentrations may inhibit 5-HT3 receptors and complicate analysis. 
